130 related articles for article (PubMed ID: 16981902)
21. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
Mohile SG; Bylow K; Dale W; Dignam J; Martin K; Petrylak DP; Stadler WM; Rodin M
Cancer; 2007 Feb; 109(4):802-10. PubMed ID: 17219443
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer.
Davison BJ; Oliffe JL; Pickles T; Mroz L
Oncol Nurs Forum; 2009 Jan; 36(1):89-96. PubMed ID: 19136342
[TBL] [Abstract][Full Text] [Related]
23. Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care.
Jacob S; Ng W; Asghari R; Delaney GP; Barton MB
Eur J Cancer; 2009 Sep; 45(14):2503-9. PubMed ID: 19527926
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!
Raghavan D
Br J Cancer; 2004 Sep; 91(6):1003-4. PubMed ID: 15475939
[No Abstract] [Full Text] [Related]
25. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL
Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158
[TBL] [Abstract][Full Text] [Related]
26. [Urological cancer].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Feb; 36(2):193-8. PubMed ID: 19223735
[TBL] [Abstract][Full Text] [Related]
27. Working patterns and perceived contribution of prostate cancer clinical nurse specialists: a mixed method investigation.
Ream E; Wilson-Barnett J; Faithfull S; Fincham L; Khoo V; Richardson A
Int J Nurs Stud; 2009 Oct; 46(10):1345-54. PubMed ID: 19358991
[TBL] [Abstract][Full Text] [Related]
28. [Does chemotherapy have a role in the treatment of prostatic cancer?].
Verbaeys A
Acta Urol Belg; 1991; 59(4):53-4. PubMed ID: 1819203
[No Abstract] [Full Text] [Related]
29. New treatment approaches for prostate cancer based on peptide analogues.
Stangelberger A; Schally AV; Djavan B
Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
Hamberg P; Verweij J; Seynaeve C
Eur J Cancer; 2007 Jul; 43(10):1514-28. PubMed ID: 17482454
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
32. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
Sartor O
J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
[No Abstract] [Full Text] [Related]
33. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
Dahm P; Yeung LL; Chang SS; Cookson MS
J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy options and outcomes in older adult patients with colorectal cancer.
Saif MW; Lichtman SM
Crit Rev Oncol Hematol; 2009 Nov; 72(2):155-69. PubMed ID: 19356946
[TBL] [Abstract][Full Text] [Related]
35. Patient comfort an important consideration for treating men with prostate cancer.
Urol Nurs; 2002 Aug; 22(4):285. PubMed ID: 12242903
[No Abstract] [Full Text] [Related]
36. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
[TBL] [Abstract][Full Text] [Related]
37. Is it justified to neglect the role of chemotherapy in the treatment of prostatic cancer?
Jasmin C; Ribaud P
Prog Clin Biol Res; 1987; 243B():255-8. PubMed ID: 3309986
[No Abstract] [Full Text] [Related]
38. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
39. Management of locally advanced prostate cancer: past, present, future.
Swanson GP
J Urol; 2006 Dec; 176(6 Pt 2):S34-41. PubMed ID: 17084164
[TBL] [Abstract][Full Text] [Related]
40. To what degree is chemotherapy useful in the treatment of prostatic cancer.
Murphy GP
Prog Clin Biol Res; 1987; 243B():247-53. PubMed ID: 3309984
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
